Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
FDF
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Alecensa
2. Alectinib
3. Ch5424802
4. Ro5424802
1. 1256589-74-8
2. Af-802 Hydrochloride
3. Alectinib Hcl
4. Alecensa
5. P9yy73lo6j
6. Alectinib Hydrochloride (jan)
7. Alectinib (hydrochloride)
8. Ch5424802 (hydrochloride)
9. Schembl14991271
10. 5h-benzo[b]carbazole-3-carbonitrile, 9-ethyl-6,11-dihydro-6,6-dimethyl-8-[4-(4-morpholinyl)-1-piperidinyl]-11-oxo-, Hydrochloride (1:1)
11. Alectinib Hydrochloride [jan]
12. 9-ethyl-6,6-dimethyl-8-[4-(morpholin-4-yl)piperidin-1-yl]-11-oxo-6,11-dihydro-5h-benzo[b]carbazole-3-carbonitrile Hydrochloride
13. Unii-p9yy73lo6j
14. Alecensa (tn)
15. 5h-benzo(b)carbazole-3-carbonitrile, 9-ethyl-6,11-dihydro-6,6-dimethyl-8-(4-(4-morpholinyl)-1-piperidinyl)-11-oxo-, Hydrochloride (1:1)
16. Alectinib Monohydrochloride
17. Af-802 (hydrochloride)
18. Agn-pc-09o9bf
19. Ro5424802 (hydrochloride)
20. Chembl3707320
21. Chebi:62268
22. Ch5424802 Hcl
23. Dtxsid10154841
24. Ch 5424802, Alectinib Hcl
25. Bcp09075
26. Ex-a1553
27. Alectinib Hydrochloride [mi]
28. Ch-5424802 Hydrochloride
29. Hy-13011a
30. Mfcd27987893
31. S5232
32. Ccg-264759
33. Cs-3480
34. Sb16516
35. Alectinib Hydrochloride [who-dd]
36. 9-ethyl-6,6-dimethyl-8-(4-morpholin-4-ylpiperidin-1-yl)-11-oxo-5h-benzo[b]carbazole-3-carbonitrile,hydrochloride
37. Ac-29721
38. As-17062
39. Alectinib Hydrochloride [orange Book]
40. D10450
41. Q27104897
42. Ch5424802 Hcl Salt, Alectinib Hcl Salt, Af802 Hcl Salt
43. Ch-5428402 Hcl; Af-802 Hydrochloride; Rg-7853 Hydrochloride; Ro-5424802 Hydrochloride
44. 9-ethyl-6,11-dihydro-6,6-dimethyl-8-[4-(4-morpholinyl)-1-piperidinyl]-11-oxo-5h-benzo[b]carbazole-3-carbonitrile Hydrochloride (1:1)
45. 9-ethyl-6,6-dimethyl-8-(4-morpholin-4-yl-piperidin-1-yl)-11-oxo-6,11-dihydro-5h-benzo[b]carbazole-3-carbonitrile Monohydrochloride Salt
46. 9-ethyl-6,6-dimethyl-8-(4-morpholin-4-ylpiperidin-1-yl)-11-oxo-5h-benzo[b]carbazole-3-carbonitrile;hydrochloride
47. Alectinib Hydrochloride;af-802 Hydrochloride;ch-5424802 Hydrochloride;rg-7853 Hydrochloride;ro-5424802 Hydrochloride
1. Alectinib
2. 1256580-46-7
3. Arq-761
4. Cas 1416163-60-4
5. Cas 1256580-46-7
Molecular Weight | 519.1 g/mol |
---|---|
Molecular Formula | C30H35ClN4O2 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 5 |
Rotatable Bond Count | 3 |
Exact Mass | 518.2448541 g/mol |
Monoisotopic Mass | 518.2448541 g/mol |
Topological Polar Surface Area | 72.4 Ų |
Heavy Atom Count | 37 |
Formal Charge | 0 |
Complexity | 867 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Alecensa as monotherapy is indicated for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).
Alecensa as monotherapy is indicated for the treatment of adult patients with ALKpositive advanced NSCLC previously treated with crizotinib.
L01ED03
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 40093
Submission : 2024-06-13
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 33869
Submission : 2019-06-12
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39383
Submission : 2024-01-30
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2019-07-19
Pay. Date : 2019-05-28
DMF Number : 33637
Submission : 2019-02-28
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2022-06-28
Pay. Date : 2022-03-15
DMF Number : 36908
Submission : 2022-03-25
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 34128
Submission : 2019-12-16
Status : Active
Type : II
Date of Issue : 2022-09-30
Valid Till : 2025-09-15
Written Confirmation Number : WC-0115A3
Address of the Firm : D-35, Industrial Area, Kalyani, Dist Nadia-741 235, West Bengal
Date of Issue : 2022-09-02
Valid Till : 2025-05-05
Written Confirmation Number : WC-0349
Address of the Firm : MIs. MSN Laboratories Private Limited, Unit-II, sv. No, 50, Kardanur (Village), ...
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Regulatory Info : RX
Registration Country : USA
Brand Name : ALECENSA
Dosage Form : CAPSULE;ORAL
Dosage Strength : EQ 150MG BASE
Packaging :
Approval Date : 2015-12-11
Application Number : 208434
Regulatory Info : RX
Registration Country : USA
Regulatory Info :
Registration Country : Switzerland
Brand Name : Alecensa
Dosage Form : Caps
Dosage Strength : 150mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info : Prescription
Registration Country : Canada
ALECTINIB (ALECTINIB HYDROCHLORIDE)
Brand Name : ALECENSARO
Dosage Form : CAPSULE
Dosage Strength : 150MG
Packaging : 240
Approval Date :
Application Number : 2458136
Regulatory Info : Prescription
Registration Country : Canada
Regulatory Info : Originator
Registration Country : South Africa
Brand Name : Alecensa
Dosage Form : CAPS
Dosage Strength : 150MG
Packaging : 224X1MG
Approval Date :
Application Number :
Regulatory Info : Originator
Registration Country : South Africa
Regulatory Info :
Registration Country : Australia
Brand Name : Alecensa
Dosage Form :
Dosage Strength :
Packaging : 224
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
Patent Expiration Date : 2032-03-04
US Patent Number : 9365514
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 208434
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2032-03-04
Patent Expiration Date : 2030-06-09
US Patent Number : 9440922
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 208434
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2030-06-09
Patent Expiration Date : 2031-05-29
US Patent Number : 9126931
Drug Substance Claim : Y
Drug Product Claim :
Application Number : 208434
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2031-05-29
Patent Expiration Date : 2035-04-24
US Patent Number : 11433076
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 208434
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2035-04-24
Patent Expiration Date : 2035-04-24
US Patent Number : 10350214
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 208434
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2035-04-24
Exclusivity Code : ODE-159
Exclusivity Expiration Date : 2024-11-06
Application Number : 208434
Product Number : 1
Exclusivity Details :
Exclusivity Code : I-947
Exclusivity Expiration Date : 2027-04-18
Application Number : 208434
Product Number : 1
Exclusivity Details :
Exclusivity Code : ODE-477
Exclusivity Expiration Date : 2031-04-18
Application Number : 208434
Product Number : 1
Exclusivity Details :
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?